Chemokines as possible therapeutic targets in metastatic melanoma
Open Access
- 11 May 2023
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 14387-14402
Abstract
Background: Cutaneous melanoma is a relentless form of cancer which continues to rise in incidence. Currently, cutaneous melanoma is the leading cause of skin cancer‐related mortality, which can mainly be attributed to its metastatic potential. The activation of chemokine axes is a major contributor to melanoma metastasis through its involvement in promoting tumour cell migration, proliferation, survival, and adhesion. This review will focus on the role of chemokines in melanoma and possible therapeutic strategies to alter chemokine activation and subsequently inhibit the activation of signalling cascades that may promote metastasis.Methods: A literature review was conducted to evaluate chemokines as possible therapeutic targets in metastatic melanoma.Results: The crosstalk between signalling pathways and immune responses in the melanoma microenvironment resembles a complex and dynamic system. Therefore, the involvement of governing chemokine axes in the promotion of cutaneous and metastatic melanoma demands a proper understanding of the tumour microenvironment in order to identify possible targets and develop appropriate treatments against melanoma.Conclusion: Even though chemokine axes are regarded as promising therapeutic targets, it has become increasingly evident that chemokines can play a critical role in both tumour inhibition and promotion. The inhibition of chemokine axes to inhibit signalling cascades in target cells that regulate metastasis should, therefore, be carefully approached.Keywords
Funding Information
- University of Pretoria (A1B523)
This publication has 108 references indexed in Scilit:
- Emerging targets in cancer management: role of the CXCL12/CXCR4 axisOncoTargets and Therapy, 2013
- Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12Cytokine & Growth Factor Reviews, 2013
- Small Molecule Inhibitors of CXCR4Theranostics, 2013
- CCL27–CCR10 and CXCL12–CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanomaClinical & Experimental Metastasis, 2012
- Inhibition of stromal CXCR4 impairs development of lung metastasesCancer Immunology, Immunotherapy, 2012
- The good and the bad of chemokines/chemokine receptors in melanomaPigment Cell & Melanoma Research, 2009
- Current concepts of metastasis in melanomaExpert Review of Dermatology, 2008
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastasesClinical & Experimental Metastasis, 2007
- Regulation of CXCR4 signalingBiochimica et Biophysica Acta (BBA) - Biomembranes, 2007
- Structural Basis of Chemokine Receptor Function—A Model for Binding Affinity and Ligand SelectivityBioscience Reports, 2006